LONG-TERM RESPONDERS WITH METASTATIC BREAST CANCER (MBC) RECEIVING ERIBULIN: REAL LIFE EXPERIENCE

e13065Background: Recently developed microtubule dynamics inhibitor eribulin mesylate (eribulin) differs from taxanes and vinca alkaloids by another mechanism of action. Here, we describe eribulin-treated MBC patients who achieved a long duration of response (DoR) in Russian clinical practice. Methods: Data for 168 MBC pts treated with eribulin between January 1 2014 and January 1 2018 were collected from different Russian centers. All these health records were retrospectively analyzed by the central institution, the Russian Oncology Research Center. Results: Our primary analysis revealed 32 (19%) pts with long DoR (8 months and more). Median age of these patients was 52 (32-67) yrs. ECOG status 0-1 was defined in 97% cases. Most of the pts (78%) had visceral metastases, median number of metastatic sites was 2 (1-5). Eighteen (56%) pts were ER/PR-positive, 7 (22%) – triple-negative, 7 (22%) – HER2-positive (eribulin was given in combination with trastuzumab). Eribulin was prescribed in the 2nd and 3rd lin...